Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HUMA with free AI briefings, catalyst countdowns, and dilution alerts.

HUMA · Humacyte, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$64.5M Cash on Hand
10.5mo Cash Runway
Follow HUMA by email Get an email when HUMA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HUMA, unsubscribe in one click. Privacy

📣 What HUMA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Acellular Tissue Engineered Vessel Vascular Injury Phase 4 · NCT07762794 Not yet recruiting
Human Acellular Vessel (HAV) Renal Failure Phase 3 · NCT02644941 Completed
Hepatitis A Virus Renal Failure Phase 2 · NCT04135417 Completed
Humacyte Coronary Tissue Engineered Vessel… Coronary Artery Disease Phase 2 · NCT07730528 Not yet recruiting
HAVG End-stage Renal Disease Phase 1 · NCT01840956 Completed
HAV implantation Trauma N/A · NCT05873959 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HUMA holds $64.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $18.5M/quarter from operations, an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 84 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HUMA files for a raise →

👥 Who Owns HUMA

Insiders 7.5% Other 5%+ holders 6.6% Institutions (182 holders) 26.4% Public and other holders 59.5%
HolderTypeShares% of sharesAs of
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
Former 10% Shareholder
Insider 18,312,735 6.59% 2021-08-26
Fresenius Medical Care AG 5%+ holder (13D) 18,312,735 6.59% 2025-10-08
Brady W Dougan
Director · +311,100 options
Insider 1,392,091 0.50% 2025-08-18
Laura E Niklason
President, CEO and Director, Director · +391,100 options
Includes shares also reported by Brady W Dougan, counted once
Insider 1,392,091 0.50% 2025-08-18
Dale A. Sander
CFO and Chief Corp. Dev. Off
Insider 307,813 0.11% 2026-05-18
Shamik J Parikh
Chief Medical Officer
Insider 272,713 0.10% 2026-05-18
Paul Brian Kuznik
Director · +125,000 options
Insider 222,238 0.08% 2026-09-22
Kathleen Sebelius
Director · +80,000 options
Insider 148,025 0.05% 2026-05-19
Keith Anthony Jones
Director · +160,000 options
Insider 50,000 0.02% 2026-09-14
Michael T. Constantino
Director · +160,000 options
Insider 43,950 0.02% 2026-05-18

Share count 277,798,105 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HUMA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HUMA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.